MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$165,767K
EPS
-$2.27
Unit: Thousand (K) dollars

Income Statement
2025-12-31
Unrealized gain (loss) on marketable securities
-94
Total other comprehensive gain (loss)
-94
Research and development
154,224
General and administrative
18,273
Total operating expenses
172,497
Loss from operations
-172,497
Other income, net
6,824
Net Income Loss
-165,700
Research and development
154,224
General and administrative
18,273
Total operating expenses
172,497
Loss from operations
-172,497
Other income, net
6,824
Net loss
-165,375
Total comprehensive loss
-165,767
Basic EPS
-2.27
Diluted EPS
-2.27
Basic Average Shares
72,947,927
Diluted Average Shares
72,947,927
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Total comprehensiveloss-$165,767K something is missing$165,402K Net Income Loss-$165,700K Net loss-$165,375K Other income, net$6,824K Other income, net$6,824K Total othercomprehensive gain (loss)-$94K Loss from operations-$172,497K Loss from operations-$172,497K Unrealized gain (loss) onmarketable securities-$94K Total operatingexpenses$172,497K Total operatingexpenses$172,497K Research and development$154,224K General andadministrative$18,273K Research and development$154,224K General andadministrative$18,273K

Larimar Therapeutics, Inc. (LRMR)

Larimar Therapeutics, Inc. (LRMR)